MedTrace Logo

Evaluating BMD in Participants ≥50 Years Old Switching From EVG/COBI/FTC/TAF or EVG/COBI/FTC/TDF to ABC/DTG/3TC

NCT03275701 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2017-09-07

No results posted yet for this study

Summary

Phase IV, Single-Arm, Open-Label Study Evaluating Bone Mineral Density in HIV-1-Infected Adults ≥50 Years Old Switching from EVG/COBI/FTC/TAF (Genvoya) or EVG/COBI/FTC/TDF (Stribild) to ABC/DTG/3TC (Triumeq)

Conditions

  • Infection, Human Immunodeficiency Virus

Interventions

DRUG

Triumeq

Open Label, Switch to Triumeq (ABC/DTG/3TC)

Sponsors & Collaborators

  • ViiV Healthcare

    collaborator INDUSTRY

  • Mills Clinical Research

    lead INDUSTRY

Principal Investigators

  • Anthony M Mills, MD · Mills Clinical Research

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-07-31
Primary Completion
2019-10-31
Completion
2019-11-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03275701 on ClinicalTrials.gov